Corgenix Receives FDA Clearance for New Diagnostic Products - Two Additional Tests Now Available to Assess Risk of Thrombosis

Apr 17, 2001, 01:00 ET from Corgenix Medical Corporation

    DENVER, April 17 /PRNewswire/ -- Corgenix Medical Corporation
 (OTC Bulletin Board:   COGX) announced today that it has received 510(k)
 clearance from the US Food and Drug Administration (FDA) to market two (2) new
 test kits for the diagnosis and risk assessment of certain cardiovascular
 disorders characterized by blood clot formation (thrombosis).  Corgenix will
 immediately begin manufacturing, distributing and marketing the tests through
 its worldwide distribution network.
     The new tests, IgG anti-Prothrombin and IgM anti-Prothrombin (aPT)
 antibody test kits are part of Corgenix ELISA diagnostic assays for
 antiphospholipid antibody detection sold to clinical laboratories.  These
 tests, the first anti-Prothrombin tests to have received FDA clearance, detect
 key markers in the blood of patients who are at risk of developing clinical
 thrombosis which can lead to heart attacks, stroke and deep vein thrombosis.
 Corgenix is a leader in the development and manufacturing of antiphospholipid
 antibody test kits, being the first on the market with FDA cleared assays for
 anti-Cardiolipin (aCL) antibodies.
     Douglass T. Simpson, president of Corgenix said, "With FDA clearance of
 these two new tests, our antiphospholipid product line increases to eleven,
 the most extensive line commercially available in this growing segment of the
 vascular-disease testing market.  Cardiovascular disease is a worldwide
 healthcare problem, and Corgenix intends to continue focusing on the
 development of innovative new products in this important area."
     According to the American Heart Association 2001 Heart and Stroke
 Statistics, 60.8 million American have some form of cardiovascular disease.
 Over 7 million of these individuals have had a myocardial infarction (heart
 attack), and 4.5 million have had a cerebrovascular accident (stroke).  In
 addition, approximately 1 million Americans develop deep vein thrombosis (DVT)
 each year and about 200,000 die of pulmonary embolism, a complication of DVT.
 
     Corgenix Medical Corporation is based in metropolitan Denver, with its
 international marketing office near Cambridge, England.  Corgenix is focused
 on the development and promotion of specialized diagnostic test kits for
 vascular diseases and immunological disorders.  Corgenix diagnostic products
 are commercialized for use in clinical laboratories worldwide.
 
     Statements in this release that are not strictly historical are "forward-
 looking" statements within the meaning of the Private Securities Litigation
 Reform Act of 1995, and should be considered as subject to various risks and
 uncertainties that could cause actual results to differ materially from those
 anticipated.  Further risks are detailed in the Company's filings with the
 Securities and Exchange Commission, including those set forth in the Company's
 most recent Annual and Quarterly Reports on Form 10-KSB and Form 10-QSB.
 
     Complete copies of the Corgenix Medical Corporation Form 10-KSB and 10-QSB
 are available at www.sec.gov, or can be obtained by contacting Chris Wolfe,
 investor relations manager of Corgenix: phone (303) 457-4345 ext. 147, or
 e-mail at cwolfe@corgenix.com.
 
 

SOURCE Corgenix Medical Corporation
    DENVER, April 17 /PRNewswire/ -- Corgenix Medical Corporation
 (OTC Bulletin Board:   COGX) announced today that it has received 510(k)
 clearance from the US Food and Drug Administration (FDA) to market two (2) new
 test kits for the diagnosis and risk assessment of certain cardiovascular
 disorders characterized by blood clot formation (thrombosis).  Corgenix will
 immediately begin manufacturing, distributing and marketing the tests through
 its worldwide distribution network.
     The new tests, IgG anti-Prothrombin and IgM anti-Prothrombin (aPT)
 antibody test kits are part of Corgenix ELISA diagnostic assays for
 antiphospholipid antibody detection sold to clinical laboratories.  These
 tests, the first anti-Prothrombin tests to have received FDA clearance, detect
 key markers in the blood of patients who are at risk of developing clinical
 thrombosis which can lead to heart attacks, stroke and deep vein thrombosis.
 Corgenix is a leader in the development and manufacturing of antiphospholipid
 antibody test kits, being the first on the market with FDA cleared assays for
 anti-Cardiolipin (aCL) antibodies.
     Douglass T. Simpson, president of Corgenix said, "With FDA clearance of
 these two new tests, our antiphospholipid product line increases to eleven,
 the most extensive line commercially available in this growing segment of the
 vascular-disease testing market.  Cardiovascular disease is a worldwide
 healthcare problem, and Corgenix intends to continue focusing on the
 development of innovative new products in this important area."
     According to the American Heart Association 2001 Heart and Stroke
 Statistics, 60.8 million American have some form of cardiovascular disease.
 Over 7 million of these individuals have had a myocardial infarction (heart
 attack), and 4.5 million have had a cerebrovascular accident (stroke).  In
 addition, approximately 1 million Americans develop deep vein thrombosis (DVT)
 each year and about 200,000 die of pulmonary embolism, a complication of DVT.
 
     Corgenix Medical Corporation is based in metropolitan Denver, with its
 international marketing office near Cambridge, England.  Corgenix is focused
 on the development and promotion of specialized diagnostic test kits for
 vascular diseases and immunological disorders.  Corgenix diagnostic products
 are commercialized for use in clinical laboratories worldwide.
 
     Statements in this release that are not strictly historical are "forward-
 looking" statements within the meaning of the Private Securities Litigation
 Reform Act of 1995, and should be considered as subject to various risks and
 uncertainties that could cause actual results to differ materially from those
 anticipated.  Further risks are detailed in the Company's filings with the
 Securities and Exchange Commission, including those set forth in the Company's
 most recent Annual and Quarterly Reports on Form 10-KSB and Form 10-QSB.
 
     Complete copies of the Corgenix Medical Corporation Form 10-KSB and 10-QSB
 are available at www.sec.gov, or can be obtained by contacting Chris Wolfe,
 investor relations manager of Corgenix: phone (303) 457-4345 ext. 147, or
 e-mail at cwolfe@corgenix.com.
 
 SOURCE  Corgenix Medical Corporation